S. 2917 — Reported in Senate

II Calendar No. 602 113th CONGRESS 2d Session S. 2917 IN THE SENATE OF THE UNITED STATES November 12, 2014Mr. Harkin (for himself, Mr. Alexander, Ms. Mikulski, Mr. Enzi, Mrs. Murray, Mr. Burr, Mr. Casey, Mr. Isakson, Mrs. Hagan, Mr. Hatch, Mr. Franken, Mr. Roberts, Mr. Bennet, Mr. Kirk, Mr. Whitehouse, Mr. Scott, Ms. Baldwin, Mr. Murphy, Ms. Warren, Ms. Klobuchar, Mr. Blumenthal, Mr. Markey, Mr. Brown, Mr. Coburn, Ms. Collins, Mr. Durbin, Mr. Kaine, Mr. Blunt, Ms. Ayotte, Mrs. Boxer, Mr. Vitter, Mr. Cornyn, Mr. McConnell, Mr. Coons, Mr. Schumer, Mr. Moran, Mr. Portman, Mr. Booker, Mrs. Feinstein, Ms. Murkowski, Mr. Chambliss, Mr. Warner, Mrs. Gillibrand, Ms. Stabenow, Mr. Heinrich, and Mrs. Shaheen) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions November 19, 2014Reported by Mr. Harkin, without amendment A BILL To expand the program of priority review to encourage treatments for tropical diseases. 1. Short title This Act may be cited as the Adding Ebola to the FDA Priority Review Voucher Program Act. 2. Priority review to encourage treatments for tropical diseases Section 524 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n) is amended— (1) in subsection (a)(3)— (A) by redesignating subparagraph (Q) as subparagraph (R); (B) by inserting after subparagraph (P) the following: (Q) Filoviruses. ; and (C) in subparagraph (R), as so redesignated, by striking regulation by and inserting order of; and (2) in subsection (b)— (A) in paragraph (2), by adding There is no limit on the number of times a priority review voucher may be transferred before such voucher is used. after the period at the end; and (B) in paragraph (4), by striking 365 days and inserting 90 days. November 19, 2014Reported without amendment